Globus Medical Q2 2026 Earnings: Margin Expansion Lifts Adjusted EPS

Globus Medical (NYSE: GMED) reported Q2 2026 net sales of $789.6 million, up 5.9% year over year, while GAAP diluted EPS fell 26.2% to $1.10 from $1.49. The GAAP decline reflected a $110.5 million Nevro bargain purchase gain in the prior-year quarter; underlying profitability improved, with non-GAAP diluted EPS rising 55.8% and adjusted EBITDA margin reaching 35.4%.

Core Earnings Data

Reported sales growth was 5.6% on a constant-currency basis, slightly below the reported rate. Management also said revenue excluding Nevro increased 9%, supported by share gains across several underlying businesses.

The contrast between GAAP and adjusted earnings was primarily caused by acquisition accounting. Although GAAP net income declined, operating income, non-GAAP EPS, adjusted EBITDA, and free cash flow all increased.

Business and Segment Performance

Musculoskeletal Solutions generated approximately $53.4 million of incremental sales, more than accounting for the company’s total increase of about $44.3 million because Enabling Technologies revenue declined. Geographically, international markets grew much faster than the United States, even after excluding currency movements.

Within the spine business, management reported 7% growth for U.S. Spine and 14% reported growth for International Spine, or 12% at constant currency. U.S. Spine recorded its fifth consecutive quarter of what management characterized as above-market growth.

Profitability, Cash Flow, and Balance Sheet

GAAP gross margin increased to 66.8% from 63.3%, while adjusted gross margin rose 200 basis points to 69.4%. The larger GAAP improvement partly reflected the absence of $6.0 million in prior-year inventory fair-value step-up amortization and lower intangible amortization included in gross profit.

Operating income also benefited from lower expenses. Selling, general and administrative expense declined to $286.8 million from $303.6 million, acquisition-related costs fell to $11.1 million from $33.2 million, and restructuring costs decreased to $2.0 million from $13.5 million. Because adjusted EBITDA excludes acquisition and restructuring items, its margin expansion indicates that the improvement was not limited to lower special costs; management also cited operating leverage and synergy realization.

Quarterly operating cash flow rose to $209.7 million, while capital expenditures declined to $33.2 million, producing company-defined free cash flow of $176.6 million. Cash, cash equivalents, and marketable securities totaled $840.5 million on June 30, 2026, up from $629.1 million at the end of 2025, with more liquidity held in marketable securities. Inventory increased to $810.9 million from $759.3 million over the same period.

Full-Year 2026 Guidance

Globus Medical reaffirmed its revenue outlook but raised its non-GAAP fully diluted EPS range by $0.25 at both ends. The combination of an unchanged sales forecast and higher earnings guidance points to greater expected profitability rather than a higher revenue assumption.

The company did not provide a quantitative reconciliation of expected non-GAAP EPS to GAAP EPS because the timing and effect of excluded acquisition, restructuring, litigation, tax, and investment-related items could not be forecast with reasonable certainty.

Recent Insider Transactions

The supplied six-month insider summary classified 82,500 shares as purchases across five transactions and 55,000 shares as sales across three transactions, resulting in net purchases of 27,500 shares, or 2.90% of reported insider holdings. Among the latest 10 individual records covering the prior two years, four were sales; the other records involved derivative exercises or conversions and a stock gift.

The supplied insider data did not identify the currency or share counts for these individual sale records. The transactions alone do not establish insiders’ views on the company’s prospects.

Risks Investors Should Watch

• Enabling Technologies contraction: Revenue in this category declined about 25.8%, offsetting part of the growth in Musculoskeletal Solutions.
• Uneven regional growth: U.S. sales increased only 3.0%, compared with 18.0% internationally. International reported growth also included a modest favorable currency effect.
• Greater reliance on margin execution: Full-year revenue guidance was unchanged while non-GAAP EPS guidance increased, making continued margin expansion, operating leverage, and synergy realization important to the updated outlook.
• Higher inventory: Inventory rose about 6.8% from year-end to $810.9 million. Its conversion into sales and cash flow is an important balance-sheet indicator.
• GAAP and non-GAAP differences: Acquisition accounting, intangible amortization, restructuring, and other excluded items continue to affect comparability between reported and adjusted earnings.

Summary

Globus Medical’s Q2 2026 results combined moderate revenue growth with substantially stronger adjusted profitability and cash generation. Musculoskeletal Solutions, U.S. Spine, and international sales drove the quarter, while Enabling Technologies declined. The main items to monitor are continued margin execution behind the raised EPS guidance, the pace of U.S. and Enabling Technologies growth, and inventory conversion.